MERCAPTOPURINE ANHYDROUS
Leukemia, T Cell
Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Leukemia, T Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid yuejun Liu | Phase 2/3 | BB |
Inno-206 Nanfang Hospital, Southern Medical University | Phase 2/3 | B |
DEXAMETHASONE Nanfang Hospital, Southern Medical University | Phase 2/3 | B |
METHOTREXATE Nanfang Hospital, Southern Medical University | Phase 2/3 | B |
Tucidinostat Nanfang Hospital, Southern Medical University | Phase 2/3 | B |
View all 12 →
Same molecule, other indications
MERCAPTOPURINE ANHYDROUS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →